United Therapeutics Corp
UTHR
NASDAQ
Biotechnology
$499.73
USD
-1.54 (-0.31%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $22.33B
Volume 472.9K
Revenue
$3.15B
TTM
+2.5%
YoY
Gross Margin
86%
TTM
-3.2%
YoY
Net Income
$1.31B
TTM
+5.5%
YoY
Operating Cash Flow
$1.69B
TTM
+22.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 798.6 | 799.5 | 790.2 | 781.5 | 783.3 |
YoY Growth | +11.7% | +6.8% | +7.4% | -1.6% | -1.9% |
Cost of Revenue | 87.6 | 100.9 | 103.4 | 133.4 | 99.5 |
Gross Profit | 711.0 | 698.6 | 686.8 | 648.1 | 683.8 |
Selling, General & Administrative | 212.5 | 182.6 | 190.6 | 184.1 | 206.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 346.5 | 310.1 | 330.1 | 322.3 | 353.0 |
Operating Income | 364.5 | 388.5 | 356.7 | 325.8 | 330.8 |
EBITDA | 385.6 | 410.4 | 379.5 | 348.4 | 355.0 |
Other Income / Expense | -0.1 | 6.1 | 47.2 | -46.3 | 13.3 |
Total Other Income / Expense | 43.9 | 49.5 | 87.3 | -7.5 | 41.9 |
Income Before Income Taxes | 408.4 | 438.0 | 444.0 | 318.3 | 372.7 |
Income Taxes | 98.9 | 99.3 | 79.7 | 43.4 | 39.7 |
Net Income | 309.5 | 338.7 | 364.3 | 274.9 | 333.0 |
Consolidated Net Income / Loss | 309.5 | 338.7 | 364.3 | 274.9 | 333.0 |
Net Income Attributable to Common Shareholders | 309.5 | 338.7 | 364.3 | 274.9 | 333.0 |
Basic EPS | $6.86 | $7.73 | $8.39 | $6.32 | $7.82 |
Diluted EPS | $6.41 | $7.16 | $7.69 | $5.82 | $7.27 |
Basic Shares Outstanding | 45.1M | 43.8M | 43.4M | 43.5M | 42.6M |
Diluted Shares Outstanding | 48.3M | 47.3M | 47.4M | 47.2M | 45.8M |